Fox Chase Cancer Center News

PHILADELPHIA (June 10, 2024) — Temple University Hospital has received re-accreditation under the American College of Surgeons (ACS) Commission on Cancer (CoC) Accreditation Program. The ACS CoC is a consortium of professional organizations dedicated to improving survival and quality of life for patients with cancer by setting and raising standards.

PHILADELPHIA (June 10, 2024)— Fox Chase Cancer Center has appointed Jeffrey M. Farma, MD, FACS, to Chair of Surgery following a succession of leadership roles at the center.

PHILADELPHIA (June 3, 2024) — Human epidermal growth factor 2 (HER2) mutations can be identified in up to 6% of non-small cell lung cancer cases where KRAS, EGFR, or ALK gene mutations are also found, according to the results of research from Temple University Hospital and Fox Chase Cancer Center presented today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

PHILADELPHIA (June 3, 2024) — A new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge and skill confidence, according to results of a pilot study presented today by Fox Chase Cancer Center researchers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

PHILADELPHIA (May 31, 2024) — Fox Chase Cancer Center and Temple Health researchers will participate in the presentation and discussion of six research projects and two other speaking engagements at the 2024 American Society of Clinical Oncology Annual Meeting, which is being held May 31-June 4 in Chicago.

PHILADELPHIA (May 29, 2024) — Researchers at Fox Chase Cancer Center have documented the first case of rectal myxoid leiomyosarcoma (MLS), a rare cancer typically seen in the female reproductive system. The researchers also found a novel fusion gene that can be used to positively identify the cancer at the molecular level.

PHILADELPHIA (May 23, 2024) — Here at Temple Health, we’re no stranger to firsts—whether that means performing a pioneering surgery, opening a new type of facility, or offering a groundbreaking treatment. That’s why it’s no surprise that we’re also leading the way in Urology care, reinforced by the recent launch of the Fox Chase-Temple Urologic Institute.

PHILADELPHIA (May 20, 2024) — Pancreatic cancer patients who received single modality neoadjuvant therapy experienced fragmented care, which is care at multiple centers, more often compared with those who received total neoadjuvant therapy, according to a study from researchers at Temple University Hospital and Fox Chase Cancer Center. The research was presented today at Digestive Disease Week (DDW).